| Literature DB >> 31426844 |
Laurence de Nijs1,2, Kyonghwan Choe3, Hellen Steinbusch3, Olaf E M G Schijns3,4,5, Jim Dings3,4,5, Daniel L A van den Hove3,6, Bart P F Rutten3, Govert Hoogland3,4,5.
Abstract
BACKGROUND: Temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS) is a common pharmaco-resistant epilepsy referred for adult epilepsy surgery. Though associated with prolonged febrile seizures (FS) in childhood, the neurobiological basis for this relationship is not fully understood and currently no preventive or curative therapies are available. DNA methylation, an epigenetic mechanism catalyzed by DNA methyltransferases (DNMTs), potentially plays a pivotal role in epileptogenesis associated with FS. In an attempt to start exploring this notion, the present cross-sectional pilot study investigated whether global DNA methylation levels (5-mC and 5-hmC markers) and DNMT isoforms (DNMT1, DNMT3a1, and DNMT3a2) expression would be different in hippocampal and neocortical tissues between controls and TLE patients with or without a history of FS.Entities:
Keywords: DNA methylation; DNA methyltransferases; Epigenetics; Febrile seizures; Temporal lobe epilepsy
Mesh:
Substances:
Year: 2019 PMID: 31426844 PMCID: PMC6701147 DOI: 10.1186/s13148-019-0721-2
Source DB: PubMed Journal: Clin Epigenetics ISSN: 1868-7075 Impact factor: 6.551
Fig. 1DNMT1 protein expression in the TLE hippocampus (a, b) and neocortex (c, d). a, c Representative Western blot showing DNMT1 (green) in the TLE hippocampus (a) and neocortex (c) compared to controls. GAPDH (red) was used as a protein loading control. b, d Graph showing semi-quantification of the Western blots for hippocampus (b) and neocortex (d). DNMT1 expression was normalized to GAPDH expression. Error bars show SEM. ***p < 0.001 for significant difference to CTRL. ††p < 0.01 and †††p < 0.001 for significant difference to HS− group. MM = molecular weight marker; CTRL = control; HS− = TLE without HS; HS+ = TLE with HS; HS+FS+ = TLE with HS and FS
Fig. 2.DNMT3a isoforms expression in the TLE hippocampus (a–c) and neocortex (d–f). a, d Representative Western blot showing DNMT3a isoforms (green) in the TLE hippocampus (a) and neocortex (d) compared to control. GAPDH (red) was used as a protein loading control. b, e Graph showing semi-quantification of the Western blots for the hippocampus (b) and neocortex (e). DNMT3a isoforms expression was normalized to GAPDH expression. c, f Real-time PCR validation of Western blots results for hippocampus (c) and neocortex (f). Error bars show SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 for significant difference to CTRL. ††p < 0.01 and †††p < 0.001 for significant difference to HS− group. ¥p < 0.05 and ¥¥p < 0.01 for significant difference to HS+ group. MM = molecular weight marker; CTRL = control; HS− = TLE without HS; HS+ = TLE with HS; HS+FS+ = TLE with HS and FS
Fig. 3DNMT3a immunoreactivity in the hippocampal DG. a Representative pictures of DNMT3a staining in the hippocampal DG of TLE patients and controls. Scale bars represent 100 μm. b ImageJ quantification of the integrated density of DNMT3a staining. c Stereological quantification of the area expressing DNMT3a. Error bars show SEM in b and CE in c. **p < 0.01 for significant difference to CTRL. †p < 0.05 and ††p < 0.01 for significant difference to HS− group. ¥ p < 0.05 for significant difference to HS+ group. CTRL = control; HS− = TLE without HS; HS+ = TLE with HS; HS+FS+ = TLE with HS and FS.
Fig. 4DNMT3a2 transcript localization in the DG of the hippocampus. a Representative pictures of DNMT3a2 in situ hybridization in the hippocampal DG of TLE patients and controls. Scale bars represent 100 μm. b ImageJ quantification of the integrated density of DNMT3a2 reactivity. c Stereological quantification of the area expressing DNMT3a2. Error bars show SEM for ImageJ and CE for stereology. **p < 0.01 and ***p < 0.001 for significant difference to CTRL. †††p < 0.01 for significant difference to HS−. ¥¥¥p < 0.001 for significant difference to HS+. CTRL = control; HS− = TLE without HS; HS+ = TLE with HS; HS+FS+ = TLE with HS and FS.
Fig. 5Global 5-mC and 5-hmc patterns in the hippocampal DG. a, d Representative pictures of 5-mC staining (a) and 5-hmc staining (d) in the hippocampal DG of TLE patients and controls. Scale bars represent 100 μm. b, e ImageJ quantification of the integrated density of 5-mc staining (b) and 5-hmc staining (e). Error bars show SEM. c, f Stereological quantification of the area expressing 5-mC staining (c) and 5-hmc staining (f). Error bars show CE. n = 3–7 per group. *p < 0.05 and ***p < 0.001 for significant difference to CTRL. ††p < 0.01 and †††p < 0.001 for significant difference to HS− group. ¥¥p < 0.01 for significant difference to HS+. CTRL = control; HS− = TLE without HS; HS+ = TLE with HS; HS+FS+ = TLE with HS and FS
Fig. 6Global 5-mC and 5-hmc patterns in the neocortex. a, c Representative pictures of 5-mC staining (a) and 5-hmc staining (c) in the neocortex of TLE patients and controls. Scale bars represent 100 μm. b, d ImageJ quantification of the integrated density of 5-mc staining (b) and 5-hmc staining (d) in the neocortex. n = 6–8 per group. Error bars show SEM. **p < 0.01 and ***p < 0.001 for significant difference to CTRL. CTRL = control; HS− = TLE without HS; HS+ = TLE with HS; HS+FS+ = TLE with HS and FS
Summary of the main findings described in this study
| Tissue | Variables measured | Methods | Groups comparison | Effect |
|---|---|---|---|---|
| Neocortex | DNMT1 | WB | All TLE groups vs CTRL | ↑ |
| Neocortex | DNMT3a1
| WB, qRT-PCR | All TLE groups vs CTRL | ↑ |
| Neocortex | 5-mC | IHC | All TLE groups vs CTRL | ↑ |
| Hippocampus | DNMT1 | WB | HS− vs CTRL | ↑ |
| Hippocampus |
| qRT-PCR, ISH | All TLE groups vs CTRL | ↓ |
| Hippocampus | DNMT3a2 | WB | HS+FS+ vs CTRL HS+FS+ vs HS− HS+FS+ vs HS+ | ↓ |
| Hippocampus | 5-mC, 5hmC | IHC | All TLE groups vs CTRL | ↓ |
| Hippocampus | DNMT3a1
| WB, qRT-PCR | HS+FS+ vs CTRL HS+FS+ vs HS− HS+FS+ vs HS+ | ↓ |
WB Western blot, TLE temporal lobe epilepsy, CTRL control, qRT-PCR quantitative reverse transcription polymerase chain reaction, IHC immunohistochemistry, ISH in situ hybridization, FS febrile seizures, HS hippocampal sclerosis
Clinical characteristics of TLE patients and post-mortem controls
| Controls | Gender | Age (years) | PMI (h) | Cause of death | Resection side | |
| C1302 | Male | 62 | 20 | Sepsis | Right | |
| C1303 | Male | 66 | 39 | Heart failure | Right | |
| C1304 | Male | 76 | 14 | Sepsis | Left | |
| C1401 | Male | 80 | 22 | Heart failure | Right | |
| C1402 | Male | 66 | 14 | Sepsis | Right | |
| C1403 | Male | 61 | 19 | Heart failure | Right | |
| C1404 | Female | 84 | 13 | Abdominal carcinoma | Right | |
| C1405 | Female | 64 | 42 | COPD | Right | |
| C1406 | Female | 85 | 17 | Lung carcinoma | Right | |
| C1407 | Male | 83 | 12 | Heart failure | Right | |
| TLE patients | Gender | Age at surgery (years) | Age of onset (years) | Duration | Pathology | Antiepileptic drugs |
| E1011 | Male | 58 | 53 | 5 | HS- | VPA, CBZ, LTG, LEV |
| E1013 | Female | 51 | 24 | 27 | HS- | LEV, CBZ, LTG |
| E1016 | Male | 37 | 31 | 6 | HS- | LEV, VPA, CBZ, LTG |
| E1107 | Female | 60 | 17 | 43 | HS- | LTG, CBZ, LEV, CLB |
| E1204 | Female | 40 | 16 | 24 | HS- | PHT, DZP, OXC, CLZ |
| E1205 | Male | 20 | N/A | N/A | HS- | N/A |
| E1206 | Male | 47 | 31 | 16 | HS- | CLB, OXC, LEV |
| E1207 | Male | 29 | 20 | 9 | HS- | OXC, LEV |
| E1214 | Female | 39 | 30 | 9 | HS- | LTG, CBZ |
| E1302 | Female | 21 | 20 | 1 | HS- | LEV, LAC |
| E1306 | Female | 59 | 7 | 52 | HS- | CBZ, CLB |
| E1319 | Female | 41 | 27 | 14 | HS- | LEV, CBZ, CLB |
| E1402 | Female | 21 | 1 | 20 | HS- | CLE, LEV |
| E1404 | Male | 19 | 8 | 8 | HS- | CBZ, CLZ, LEV |
| E1009 | Female | 39 | 4 | 35 | HS+ | DZP, CLB, LEV, OXC |
| E1018 | Male | 63 | 2.5 | 60.5 | HS+ | CBZ, CLB, PHT, CLZ |
| E1019 | Female | 43 | 3 | 40 | HS+ | LTG, CLZ, DZP, LEV, CLB |
| E1103 | Female | 58 | 54 | 4 | HS+ | LTG, LEV, OXC, CBZ |
| E1104 | Male | 47 | 3 | 44 | HS+ | LEV, PHT |
| E1217 | Male | 54 | 17 | 37 | HS+ | FLU, LTG, MET, ZOP |
| E1218 | Male | 28 | 4 | 24 | HS+ | CBZ, LTG |
| E1312 | Female | 23 | 19 | 4 | HS+ | MDZ |
| E1318 | Female | 47 | 11 | 36 | HS+ | LTG, CLB, TMP, VPA |
| E1407 | Male | 55 | 10 | 45 | HS+ | MDZ, CBZ, CLB, LEV |
| E0109 | Male | 48 | 30 | 18 | HS+FS+ | LTG, CLB, TPM |
| E0705 | Female | 23 | 6 | 16 | HS+FS+ | LEV, LTG, CLB |
| E0707 | Female | 59 | N/A | N/A | HS+FS+ | OXC, CLB, LEV |
| E1014 | Female | 50 | 47 | 3 | HS+FS+ | OXC, LEV, CLB |
| E1017 | Female | 23 | 1 | 22 | HS+FS+ | LTG, TPM, CLB, OXC |
| E1213 | Male | 60 | 2 | 58 | HS+FS+ | CBZ, VPA, LTG, DZP |
| E1219 | Male | 36 | 9 | 27 | HS+FS+ | LEV, VPA, OXC |
| E1221 | Female | 41 | 4 | 37 | HS+FS+ | CLZ, CBZ |
| E1305 | Female | 20 | 1 | 19 | HS+FS+ | MDZ, LEV, TMP |
| E1310 | Female | 43 | 28 | 15 | HS+FS+ | LEV, LTG, CLB |
| E1314 | Male | 42 | 8 | 34 | HS+FS+ | LTG, CLB |
| E1408 | Male | 33 | 0 | 33 | HS+FS+ | CBZ, CLB, MDZ |
| E1416 | Female | 41 | 20 | 21 | HS+FS+ | LEV, LTG, CLB |
CBZ carbamazepine, CLB clobazam, CLZ clonazepam, DZP diazepam, FLU flupentixol, FS febrile seizures, HS hippocampal sclerosis, LAC lascosamide, LEV levotiracetam, LTG lamotrigine, MDZ midazolam, MET methotrimeprazine, OXC oxcarbazepine, PHT phenytoin, PMI post-mortem interval, TLE temporal lobe epilepsy, TPM topiramate, VPA valproic acid, ZOP zopiclone, N/A not available